Handel Alimera Sciences, Inc. - ALIM CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.28 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.025457% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.003235% | ||||||||
Gebyr natten over, tid | 21:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Tidligere luk* | 2.52 |
Åben* | 2.52 |
1-Års Ændring* | -54.84% |
Dagens Spænd* | 2.5 - 2.66 |
52-Ugers Spænd | 1.30-7.92 |
Gennemsnitlig Volumen (10 dage) | 3.75M |
Gennemsnitlig Volumen (3 måneder) | 12.93M |
Market Cap | 19.33M |
P/E-forhold | -100.00K |
Udestående aktier | 7.40M |
Omsætning | 55.78M |
EPS | -2.44 |
Dividend (Udbytte %) | N/A |
Beta | 1.39 |
Næste indtjeningsopgørelse | Jul 25, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Jun 2, 2023 | 2.57 | 0.06 | 2.39% | 2.51 | 2.66 | 2.50 |
Jun 1, 2023 | 2.52 | -0.08 | -3.08% | 2.60 | 2.60 | 2.51 |
May 31, 2023 | 2.67 | 0.19 | 7.66% | 2.48 | 2.67 | 2.48 |
May 30, 2023 | 2.52 | 0.05 | 2.02% | 2.47 | 2.55 | 2.47 |
May 26, 2023 | 2.49 | 0.08 | 3.32% | 2.41 | 2.52 | 2.35 |
May 25, 2023 | 2.48 | -0.02 | -0.80% | 2.50 | 2.51 | 2.37 |
May 24, 2023 | 2.41 | 0.23 | 10.55% | 2.18 | 2.42 | 2.14 |
May 23, 2023 | 2.32 | -0.19 | -7.57% | 2.51 | 2.55 | 2.21 |
May 22, 2023 | 2.45 | 0.28 | 12.90% | 2.17 | 2.72 | 2.15 |
May 19, 2023 | 2.23 | 0.12 | 5.69% | 2.11 | 2.30 | 2.02 |
May 18, 2023 | 2.34 | -0.26 | -10.00% | 2.60 | 3.05 | 2.26 |
May 17, 2023 | 1.93 | 0.11 | 6.04% | 1.82 | 1.94 | 1.78 |
May 16, 2023 | 1.79 | 0.21 | 13.29% | 1.58 | 1.92 | 1.58 |
May 15, 2023 | 1.57 | -0.03 | -1.88% | 1.60 | 1.68 | 1.56 |
May 12, 2023 | 1.56 | -0.05 | -3.11% | 1.61 | 1.64 | 1.55 |
May 11, 2023 | 1.57 | 0.02 | 1.29% | 1.55 | 1.64 | 1.48 |
May 10, 2023 | 1.52 | -0.11 | -6.75% | 1.63 | 1.85 | 1.51 |
May 9, 2023 | 1.63 | -0.14 | -7.91% | 1.77 | 1.77 | 1.63 |
May 8, 2023 | 1.73 | -0.06 | -3.35% | 1.79 | 1.80 | 1.73 |
May 5, 2023 | 1.83 | -0.05 | -2.66% | 1.88 | 2.04 | 1.76 |
Alimera Sciences, Inc. Events
Tid (UTC) (UTC) | Land | Begivenhed |
---|---|---|
Wednesday, July 12, 2023 | ||
Tid (UTC) (UTC) 13:30 | Land US
| Begivenhed Alimera Sciences Inc Annual Shareholders Meeting Alimera Sciences Inc Annual Shareholders MeetingForecast -Previous - |
Tuesday, July 25, 2023 | ||
Tid (UTC) (UTC) 12:30 | Land US
| Begivenhed Q2 2023 Alimera Sciences Inc Earnings Release Q2 2023 Alimera Sciences Inc Earnings ReleaseForecast -Previous - |
Monday, November 13, 2023 | ||
Tid (UTC) (UTC) 13:30 | Land US
| Begivenhed Q3 2023 Alimera Sciences Inc Earnings Release Q3 2023 Alimera Sciences Inc Earnings ReleaseForecast -Previous - |
- Årlig
- Pr kvartal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total omsætning | 54.129 | 59.029 | 50.82 | 53.943 | 46.599 |
Omsætning | 54.129 | 59.029 | 50.82 | 53.943 | 46.599 |
Kost af omsætning, Total | 7.977 | 7.03 | 6.941 | 6.626 | 4.308 |
Bruttofortjeneste | 46.152 | 51.999 | 43.879 | 47.317 | 42.291 |
Totale Driftsudgifter | 65.769 | 57.438 | 51.321 | 59.217 | 58.035 |
Salgs/Generelle/Admin. Udgifter, Total | 38.858 | 35.843 | 32.036 | 38.958 | 38.042 |
Forskning & Udvikling | 16.228 | 13.778 | 9.668 | 10.992 | 11.274 |
Depreciation / Amortization | 2.706 | 2.579 | 2.676 | 2.641 | 2.645 |
Usædvanlig Udgift (Indkomst) | 0 | -1.792 | 0 | 1.766 | |
Driftsindtægter | -11.64 | 1.591 | -0.501 | -5.274 | -11.436 |
Renteindkomst (Udgift), Netto Ikke-Drift | -5.789 | -4.997 | -4.906 | -4.953 | -4.84 |
Netto Indkomst Før Skat | -18.079 | -3.934 | -5.407 | -10.227 | -16.276 |
Netto Indkomst Efter Skat | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Netto Indkomst Før Ekstra Ting | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Netto Indkomst | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
Fortyndet Netto Indkomst | -18.107 | -4.372 | -5.339 | -10.443 | 21.948 |
Fortyndet Vægtet Gennemsnit Aktier | 6.99685 | 6.59524 | 5.11766 | 4.7702 | 5.91587 |
Fortyndet EPS Uden Ekstraordinære Ting | -2.58788 | -0.6629 | -1.04325 | -2.18921 | 3.71002 |
Fortyndet Normaliseret EPS | -2.58788 | -0.83951 | -1.04325 | -2.18921 | 3.90406 |
Other Operating Expenses, Total | |||||
Totale Ekstraordinære Ting | 0 | 0 | |||
Total Adjustments to Net Income | 0 | 38.33 | |||
Andre, Netto | -0.65 | -0.528 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total omsætning | 13.546 | 14.029 | 13.598 | 14.604 | 11.898 |
Omsætning | 13.546 | 14.029 | 13.598 | 14.604 | 11.898 |
Kost af omsætning, Total | 2.028 | 2.125 | 2.006 | 2.166 | 1.68 |
Bruttofortjeneste | 11.518 | 11.904 | 11.592 | 12.438 | 10.218 |
Totale Driftsudgifter | 16.848 | 16.137 | 17.009 | 16.578 | 16.045 |
Salgs/Generelle/Admin. Udgifter, Total | 9.975 | 9.099 | 9.856 | 9.81 | 10.093 |
Forskning & Udvikling | 4.164 | 4.23 | 4.483 | 3.932 | 3.583 |
Depreciation / Amortization | 0.681 | 0.683 | 0.664 | 0.67 | 0.689 |
Driftsindtægter | -3.302 | -2.108 | -3.411 | -1.974 | -4.147 |
Renteindkomst (Udgift), Netto Ikke-Drift | -1.68 | -1.621 | -1.567 | -1.345 | -1.256 |
Netto Indkomst Før Skat | -4.968 | -3.781 | -5.245 | -3.098 | -5.955 |
Netto Indkomst Efter Skat | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
Netto Indkomst Før Ekstra Ting | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
Netto Indkomst | -4.968 | -3.78 | -5.257 | -3.115 | -5.955 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
Fortyndet Netto Indkomst | -4.982 | -3.78 | -5.257 | -3.115 | -5.955 |
Fortyndet Vægtet Gennemsnit Aktier | 7.03223 | 7.00032 | 6.99658 | 6.99971 | 6.99074 |
Fortyndet EPS Uden Ekstraordinære Ting | -0.70845 | -0.53998 | -0.75137 | -0.44502 | -0.85184 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Fortyndet Normaliseret EPS | -0.70845 | -0.53998 | -0.75137 | -0.44502 | -0.85184 |
Usædvanlig Udgift (Indkomst) | 0 | 0 | 0 | ||
Andre, Netto | 0.014 | -0.052 | -0.267 | 0.221 | -0.552 |
Total Adjustments to Net Income | -0.014 |
- Årlig
- Pr kvartal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 29.413 | 42.16 | 34.906 | 32.745 | 34.848 |
Likvider og Kortsigtede Investeringer | 5.274 | 16.51 | 11.208 | 9.426 | 13.043 |
Likvider & Lignende | 5.274 | 16.51 | 11.208 | 9.426 | 13.043 |
Totale Tilgodehavender, Netto | 19.612 | 19.128 | 17.2 | 19.331 | 17.259 |
Accounts Receivable - Trade, Net | 19.612 | 19.128 | 17.2 | 19.331 | 17.259 |
Total Inventory | 1.605 | 2.679 | 2.746 | 1.39 | 2.405 |
Prepaid Expenses | 2.892 | 3.809 | 3.718 | 2.565 | 2.109 |
Other Current Assets, Total | 0.03 | 0.034 | 0.034 | 0.033 | 0.032 |
Total Assets | 42.602 | 58.52 | 50.855 | 50.309 | 54.108 |
Property/Plant/Equipment, Total - Net | 3.92 | 4.493 | 2.358 | 2.047 | 1.355 |
Property/Plant/Equipment, Total - Gross | 7.981 | 7.923 | 6.305 | 5.858 | 4.967 |
Accumulated Depreciation, Total | -4.061 | -3.43 | -3.947 | -3.881 | -3.612 |
Intangibles, Net | 8.957 | 10.897 | 12.838 | 14.783 | 16.723 |
Other Long Term Assets, Total | 0.129 | 0.137 | 0.753 | 0.734 | 1.182 |
Total Current Liabilities | 39.732 | 12.592 | 12.348 | 12.048 | 10.234 |
Accounts Payable | 10.088 | 8.706 | 7.461 | 7.077 | 6.355 |
Accrued Expenses | 3.998 | 3.617 | 3.197 | 4.716 | 3.643 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 25.646 | 0.269 | 1.69 | 0.255 | 0.236 |
Other Current Liabilities, Total | |||||
Total Liabilities | 63.41 | 61.125 | 58.833 | 54.754 | 51.386 |
Total Long Term Debt | 18.683 | 43.08 | 42.922 | 38.752 | 38.178 |
Long Term Debt | 18.683 | 43.08 | 42.408 | 38.658 | 37.873 |
Capital Lease Obligations | 0.514 | 0.094 | 0.305 | ||
Other Liabilities, Total | 4.995 | 5.453 | 3.563 | 3.954 | 2.974 |
Total Equity | -20.808 | -2.605 | -7.978 | -4.445 | 2.722 |
Preferred Stock - Non Redeemable, Net | 19.227 | 19.227 | 19.227 | 30.344 | 30.344 |
Common Stock | 0.07 | 0.069 | 0.057 | 0.05 | 0.701 |
Additional Paid-In Capital | 378.238 | 377.229 | 365.83 | 350.117 | 346.108 |
Retained Earnings (Accumulated Deficit) | -415.388 | -397.281 | -392.539 | -383.863 | -373.42 |
Other Equity, Total | -2.955 | -1.849 | -0.553 | -1.093 | -1.011 |
Total Liabilities & Shareholders’ Equity | 42.602 | 58.52 | 50.855 | 50.309 | 54.108 |
Total Common Shares Outstanding | 6.99551 | 6.93515 | 5.71937 | 4.96595 | 4.67193 |
Total Preferred Shares Outstanding | 0.6 | 0.6 | 0.6 | 0.61015 | 0.61015 |
Long Term Investments | 0.183 | 0.833 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 35.675 | 29.413 | 29.76 | 33.073 | 34.753 |
Likvider og Kortsigtede Investeringer | 13.086 | 5.274 | 5.514 | 7.859 | 9.946 |
Likvider & Lignende | 13.086 | 5.274 | 5.514 | 7.859 | 9.946 |
Totale Tilgodehavender, Netto | 18.433 | 19.612 | 19.142 | 20.319 | 18.776 |
Accounts Receivable - Trade, Net | 18.433 | 19.612 | 19.142 | 20.319 | 18.776 |
Total Inventory | 1.215 | 1.605 | 1.786 | 1.656 | 2.452 |
Prepaid Expenses | 2.91 | 2.892 | 3.29 | 3.208 | 3.546 |
Other Current Assets, Total | 0.031 | 0.03 | 0.028 | 0.031 | 0.033 |
Total Assets | 48.239 | 42.602 | 43.429 | 47.574 | 49.931 |
Property/Plant/Equipment, Total - Net | 3.757 | 3.92 | 3.87 | 3.938 | 4.343 |
Intangibles, Net | 8.479 | 8.957 | 9.446 | 9.935 | 10.419 |
Other Long Term Assets, Total | 0.131 | 0.129 | 0.118 | 0.126 | 0.134 |
Total Current Liabilities | 14.173 | 39.732 | 34.01 | 25.431 | 17.006 |
Accounts Payable | 9.669 | 10.088 | 8.706 | 7.614 | 6.604 |
Accrued Expenses | 4.241 | 3.998 | 3.661 | 3.316 | 3.046 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.263 | 25.646 | 21.643 | 14.501 | 7.356 |
Total Liabilities | 67.155 | 63.41 | 61.507 | 59.909 | 58.534 |
Total Long Term Debt | 44.312 | 18.683 | 22.492 | 29.297 | 36.245 |
Long Term Debt | 44.152 | 18.683 | 22.492 | 29.297 | 36.245 |
Capital Lease Obligations | 0.16 | ||||
Other Liabilities, Total | 8.67 | 4.995 | 5.005 | 5.181 | 5.283 |
Total Equity | -18.916 | -20.808 | -18.078 | -12.335 | -8.603 |
Preferred Stock - Non Redeemable, Net | 7.728 | 19.227 | 19.227 | 19.227 | 19.227 |
Common Stock | 0.074 | 0.07 | 0.07 | 0.07 | 0.07 |
Additional Paid-In Capital | 378.146 | 378.238 | 378.005 | 377.847 | 377.541 |
Retained Earnings (Accumulated Deficit) | -402.081 | -415.388 | -411.608 | -406.351 | -403.236 |
Other Equity, Total | -2.783 | -2.955 | -3.772 | -3.128 | -2.205 |
Total Liabilities & Shareholders’ Equity | 48.239 | 42.602 | 43.429 | 47.574 | 49.931 |
Total Common Shares Outstanding | 7.39159 | 6.99551 | 6.99802 | 6.99546 | 6.99265 |
Total Preferred Shares Outstanding | 0.012 | 0.6 | 0.6 | 0.6 | 0.6 |
Long Term Investments | 0.197 | 0.183 | 0.235 | 0.502 | 0.282 |
Other Current Liabilities, Total |
- Årlig
- Pr kvartal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netto indkomst/Startlinje | -18.107 | -4.372 | -5.339 | -10.443 | -16.382 |
Likvider Fra Driftsaktiviteter | -9.975 | -3.224 | -2.193 | -4.152 | -11.553 |
Likvider Fra Driftsaktiviteter | 2.706 | 2.579 | 2.676 | 2.641 | 2.645 |
Deferred Taxes | 0.116 | 0.61 | 0.031 | 0.454 | -0.653 |
Ikke-Likvide Ting | 2.621 | -0.692 | 1.829 | 3.377 | 7.084 |
Cash Taxes Paid | 0.232 | 0.112 | 0.11 | 0.239 | 0.239 |
Likvid Rente Betalt | 4.489 | 4.302 | 4.556 | 4.419 | 3.571 |
Ændringer i Driftskapital | 2.689 | -1.349 | -1.39 | -0.181 | -4.247 |
Likvider fra Investeringsaktiviteter | -0.255 | -0.621 | -0.62 | -0.174 | -0.175 |
Kapitaludgifter | -0.255 | -0.621 | -0.62 | -0.174 | -0.175 |
Likvider fra Financieringsaktiviteter | -0.302 | 9.823 | 3.882 | 0.869 | 0.95 |
Financiering af Cash-Flow-Ting | -0.113 | 0 | -0.019 | -2.227 | -3.808 |
Udstedelse (Pensionering) af Aktier, Netto | 0.1 | 10.044 | 0.049 | 0.902 | 0.085 |
Udstedelse (Pensionering) af Gæld, Netto | -0.289 | -0.221 | 3.852 | 2.194 | 4.673 |
Udenlandsk Børs Effekter | -0.708 | -0.676 | 0.714 | -0.159 | -0.248 |
Netto Ændring i Likviditet | -11.24 | 5.302 | 1.783 | -3.616 | -11.026 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.968 | -18.107 | -14.327 | -9.07 | -5.955 |
Cash From Operating Activities | -2.209 | -9.975 | -9.724 | -7.811 | -6.213 |
Cash From Operating Activities | 0.681 | 2.706 | 2.023 | 1.359 | 0.689 |
Non-Cash Items | 0.507 | 2.621 | 2.095 | 1.318 | 1.027 |
Cash Taxes Paid | 0 | 0.232 | 0.224 | 0.182 | 0.018 |
Cash Interest Paid | 1.354 | 4.489 | 3.253 | 2.145 | 1.061 |
Changes in Working Capital | 1.571 | 2.689 | 0.485 | -1.418 | -1.974 |
Cash From Investing Activities | -0.009 | -0.255 | -0.171 | -0.041 | -0.149 |
Capital Expenditures | -0.009 | -0.255 | -0.171 | -0.041 | -0.149 |
Cash From Financing Activities | 9.998 | -0.302 | -0.109 | -0.164 | -0.062 |
Financing Cash Flow Items | -3.123 | -0.113 | |||
Issuance (Retirement) of Debt, Net | 2.373 | -0.289 | -0.164 | -0.204 | -0.062 |
Foreign Exchange Effects | 0.033 | -0.708 | -0.998 | -0.638 | -0.141 |
Net Change in Cash | 7.813 | -11.24 | -11.002 | -8.654 | -6.565 |
Issuance (Retirement) of Stock, Net | 10.748 | 0.1 | 0.055 | 0.04 | |
Deferred Taxes | 0.116 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
Velan Capital Investment Management LP | Investment Advisor/Hedge Fund | 22.4131 | 1659654 | 1401901 | 2023-05-17 | MED |
Ocumension Therapeutics | Corporation | 15.4621 | 1144945 | 0 | 2023-04-24 | LOW |
Morgan Stanley & Co. LLC | Research Firm | 8.9243 | 660832 | 0 | 2023-03-31 | MED |
Caligan Partners, LP | Hedge Fund | 6.4657 | 478777 | 0 | 2023-05-17 | MED |
Eiswirth (Richard S Jr) | Individual Investor | 4.3555 | 322518 | 500 | 2023-04-24 | LOW |
HOOPP Investment Management | Pension Fund | 3.3762 | 250000 | 0 | 2023-03-31 | HIGH |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.0071 | 148624 | 0 | 2023-03-31 | LOW |
Ashman Philip | Individual Investor | 1.8004 | 133315 | 0 | 2023-04-24 | MED |
Holland (David R) | Individual Investor | 1.4704 | 108880 | 500 | 2023-04-24 | LOW |
Renaissance Technologies LLC | Hedge Fund | 1.3693 | 101394 | -1100 | 2023-03-31 | HIGH |
Skibsted (Russell L) | Individual Investor | 1.0196 | 75500 | 58000 | 2023-03-26 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5167 | 38262 | 0 | 2023-03-31 | LOW |
Jones (John Philip) | Individual Investor | 0.4347 | 32186 | 372 | 2022-10-31 | |
Millennium Management LLC | Hedge Fund | 0.3884 | 28762 | 16799 | 2023-03-31 | HIGH |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.2639 | 19542 | 0 | 2023-03-31 | MED |
Bridgeway Capital Management, LLC | Investment Advisor | 0.2471 | 18300 | 0 | 2023-03-31 | LOW |
Perritt Capital Management, Inc. | Investment Advisor | 0.2431 | 18000 | 0 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.175 | 12962 | 438 | 2023-03-31 | LOW |
J.P. Morgan Securities LLC | Research Firm | 0.14 | 10364 | 9838 | 2023-03-31 | MED |
Snisarenko (John) | Individual Investor | 0.135 | 10000 | 0 | 2023-04-24 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group535K+
Handlende
87K+
Månedlkige, aktive klienter
$113M+
Månedlig investeringsvolumen
$64M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Alimera Sciences, Inc. Company profile
Om Alimera Sciences, Inc.
Alimera Sciences, Inc. er en lægemiddelvirksomhed. Virksomheden beskæftiger sig med markedsføring og udvikling af receptpligtige oftalmiske lægemidler. Selskabet fokuserer på sygdomme, der påvirker bagsiden af øjet eller nethinden. Selskabets kommercielle produkt, ILUVIEN, er et intravitrealt implantat, som behandler patienter ved at afgive en kontinuerlig mikrodosis af det ikke-proprietære kortikosteroid fluocinolonacetonid (FAc) i øjet i op til 36 måneder. Virksomheden er engageret i udvikling til behandling af diabetisk makulaødem (DME). DME er en sygdom i nethinden, der rammer personer med diabetes og kan føre til alvorligt synstab og blindhed. ILUVIEN kan også bruges til at forebygge tilbagefald ved tilbagevendende ikke-infektiøs uveitis, der påvirker det bageste segment af øjet (NIU-PS). Virksomheden markedsfører ILUVIEN direkte i USA, Tyskland, Det Forenede Kongerige, Portugal og Irland.
Industry: | Biopharmaceuticals |
Ste 290
6120 Windward Parkway
ALPHARETTA
GEORGIA 30005
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 535.000+ handlende over hele verden, der valgte at handle hos Capital.com